1-6 of 6
Linda Hanssens
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL

Francesca del Bufalo, Marco Becilli, Chiara Rosignoli, Biagio De Angelis, Mattia Algeri, Linda Hanssens, Monica Gunetti, Stefano Iacovelli, Giuseppina Li Pira, Elia Girolami, Giovanna Leone, Stefania Lazzaro, Valentina Bertaina, Matilde Sinibaldi, Stefano Di Cecca, Laura Iaffaldano, Annette Künkele, Emilia Boccieri, Giada Del Baldo, Daria Pagliara, Pietro Merli, Roberto Carta, Concetta Quintarelli, Franco Locatelli
Journal: Blood
Blood (2023) 142 (2): 146–157.
https://doi.org/10.1182/blood.2023020023
Published: 2023
Includes: Supplemental data
Journal Articles

A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nadine Kutsch, Philipp Gödel, Udo Holtick, Anja Lohneis, Vladan Vucinic, Florentine Pia Altefrohne, Christin Schubert, Sandra Karitzky, Linda Hanssens, Mario Assenmacher, Iris Bürger, Murat Aktas, Peter Borchmann
Journal: Blood
Blood (2022) 140 (Supplement 1): 12980–12981.
https://doi.org/10.1182/blood-2022-168730
Published: 2022
Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten
Journal: Blood
Blood (2022) 140 (Supplement 1): 12784–12785.
https://doi.org/10.1182/blood-2022-164650
Published: 2022
Journal Articles

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tatjana Holzer, Stefanie Biedermann, Inga Herfort, Birte Friedrichs, Silke Holtkamp, Linda Hanssens, Mario Assenmacher, Ulf Bethke, Dina Schneider, Stefan Miltenyi, Toon Overstijns, Christoph Schmid, Francis A. Ayuk, Christoph Scheid, Anja Jühling, Udo Holtick, Philipp Gödel, Peter Borchmann, Iris Bürger
Journal: Blood
Blood (2022) 140 (Supplement 1): 4581–4583.
https://doi.org/10.1182/blood-2022-164597
Published: 2022
Journal Articles

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Andreas Mackensen, Linda Hanssens, Matthias Stelljes, Wolfgang A Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, Alisa Yakushina, Sandra Karitzky, Silke Holtkamp, Mario Assenmacher, Marion Jurk, Georg Rauser, Dina Schneider, Claudia Rossig
Journal: Blood
Blood (2021) 138 (Supplement 1): 3836.
https://doi.org/10.1182/blood-2021-152452
Published: 2021
Journal Articles

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Peter Borchmann, Anja Jühling, Philipp Gödel, Hyatt Balke-Want, Christoph Schmid, Francis A. Ayuk, Silke Holtkamp, Liane Preussner, Gregor Zadoyan, Linda Hanssens, Andrew Kaiser, Marion Jurk, Iris Bürger, Dina Schneider, Boro Dropulic, Toon Overstijns, Christof Scheid, MD, Udo Holtick, Stefan Miltenyi, Michael Hallek
Journal: Blood
Blood (2020) 136 (Supplement 1): 48.
https://doi.org/10.1182/blood-2020-136067
Published: 2020